Abstract: Disclosed herein are methods for N-demethylating an N-methylated compound using an enzymatic reaction, rather than, e.g. a chemical modification. Also provided herein are enzymes for performing the reaction.

Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuron. The present invention also provides methods of screening compounds that modulate activity of an ActRII protein and/or an ActRII ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRII protein and/or an ActRII ligand.

Abstract: Described herein are recombinant yeast cells expressing a xylulose kinase (XK) which are suitable for fermentation of pentoses. Also described are recombinant yeast cells with higher tolerance to formic and/or acetic acid and suitable for fermentation of pentoses. Also described are recombinant yeast cells expressing an enolase, a phosphofructokinase beta subunit, a 6-phosphofructo-2-kinase, a glucose-6-phosphate isomerase, a phosphoglycerate mutase and/or a triose-phosphate isomerase, and suitable for fermentation of pentoses. Also described are recombinant yeast cells expressing a phosphoglucomutase and/or phosphoribomutase which are suitable for fermentation of pentoses. Further described are methods of using or producing such recombinant yeast cells and related materials.

Abstract: Provided are compositions comprising recombinant polymerases that include amino acid substitutions, insertions, deletions, and/or exogenous features that confer modified properties upon the polymerase for sequencing RNA or RNA/DNA templates. Polymerases that topologically encircle the template nucleic acid are provided. Also provided are methods of using such polymerases to make a DNA or to sequence a template comprising RNA.

Abstract: The present invention relates to a recombinant microorganism to which a gene coding for 2-hydroxyisocaproate-CoA transferase and a gene coding for polyhydroxyalkanoate synthase are introduced and which has a potential of producing polyhydroxyalkanoate bearing an aromatic monomer or a long-chain 2-HA monomer and a method for producing polyhydroxyalkanoate bearing an aromatic monomer or a long-chain 2-HA monomer, using the recombinant microorganism. According to the present invention, a biodegradable polymer bearing an aromatic monomer or a long-chain 2-HA monomer can be produced.

Abstract: Provided herein are substantially non-luminescent peptide/polypeptide tags that are inserted internally within a protein of interest or between N-terminal and C-terminal peptides/polypeptides. Interaction of the internally-inserted tag with a complement polypeptide/peptide that is also substantially non-luminescent results in the formation a bioluminescent reporter complex.

Abstract: The present invention pertains to a novel treatment of pathologies caused by an increased synthesis or accumulation of sulfolipids such as sulfatide. The invention provides mutated arylsulfatase A (ARSA or ASA, EC 3.1.6.8) enzymes with increased activity towards sulfatide metabolization. The invention provides nucleic acids encoding the mutant ARSA, the use of the proteins and nucleic acids, as well as pharmaceutical compositions comprising them, in the treatment of lysosomal storage disorders (LSDs) such as metachromatic leukodystrophy (MLD).

Abstract: Provided are mutant cocaine esterase polypeptides and PEGylated formulations thereof.

Abstract: The present invention relates to artificial molecular complexes comprising at least one site-specific nuclease and directly in interacting therewith at least one repair template docking domain, said repair template docking domain interacting with at least one repair template nucleic acid sequence. The artificial complex can further comprise at least one interaction domain. The artificial molecular complexes are configured to mediate repair of a DNA target sequence in a prokaryotic or eukaryotic organism with high precision in a targeted way and can thus be used for genome engineering in a prokaryotic or a eukaryotic cell or organism, or editing of a viral genome. Further provided are methods of modifying at least one DNA target sequence in a prokaryotic or eukaryotic cell or a viral genome, e.g., for trait development, or for treating a disease.

Abstract: The present invention relates to polypeptides having xylanase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. The invention also relates to compositions comprising the polypeptides of the invention and the use of the polypeptides of the invention to solubilise xylan and in animal feed.

Abstract: The present invention relates to variants of a parent alpha-amylase. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: The present invention relates to protease variants, having improved properties compared to the parent protease, in particular variants of a serine protease belonging to family 53 derived from a strain of Meripilus giganteus. The variants according to the invention have in particular increased thermo-stability, e.g., increased residual activity after 30 min at a temperature in the range from 55 to 60° C. and/or increased thermal denaturation temperature, compared to the parent Meripilus giganteus protease. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: The present invention provides a fungus of the genus Rhizopus having high productivity of an organic acid. The present invention also provides a mutant of the genus Rhizopus with reduced pyruvate decarboxylase activity.

Abstract: Disclosed is an expression vector comprising a polynucleotide encoding for a glutamine synthetase with reduced activity compared to a wild type glutamine synthetase. Also disclosed are host cells, methods for preparing stable cell line, methods of producing polypeptide of interest, and kits thereof.

Abstract: Engineered transcriptional activator-like effectors (TALEs) are versatile tools for genome manipulation with applications in research and clinical contexts. One current drawback of TALEs is their tendency to bind and cleave off-target sequence, which hampers their clinical application and renders applications requiring high-fidelity binding unfeasible. This disclosure provides engineered TALE domains and TALEs comprising such engineered domains, e.g., TALE nucleases (TALENs), TALE transcriptional activators, TALE transcriptional repressors, and TALE epigenetic modification enzymes, with improved specificity and methods for generating and using such TALEs.

Abstract: Methods for simplified, rapid gel electrophoresis size-purification and downstream sequencing of an Oligo Library, for example an miRNA Library, based on co-purifying a DNA ladder molecular weight standard customized to co-migrate with Library to provide highly salient bands on the gel at the upper and lower ends of the Library size range, permitting precise cutting and avoiding the negative effects of gel distortion, variation of DNA migration rate in different lanes, and the difficulty of matching sample to ladder across a large distance. The methods may be applied to increase yield and purity in an Oligo Library of low-quality or low input Oligo, and in particular in small RNA samples.

Abstract: The present invention relates to an inducible CRISPR RNA comprising a spacer-blocking element, a cleavable loop element and a CRISPR sgRNA comprising a spacer element (guide sequence). The invention also provides methods of using inducible CRISPR RNA/CRISPR enzyme complexes.

Abstract: Methods and compositions are provided for assembly of large nucleic acids where the assembled large nucleic acids lack internal sequence modifications made during the assembly process.

Abstract: The present application provides a method of producing a “liquid” array of ligand (such as glycan) modified bacteriophage where the ligand modification is encoded genetically within the bacteriophage genome. This method will allow for the determination of the ligand binding profile of biomacromolecules and cells. Furthermore the method allows the elucidation of ligand-protein interactions where ligand binding is co-operative and synergistic.

Abstract: This invention relates to modular proteins that interact with one or more target molecules. The chimeric proteins comprise two or more repeat domains, such as tetratricopeptide repeat domains; inter-repeat loops linking the repeat domains; and one or more peptide ligands. Each peptide ligand is located in an inter-repeat loop or at the N or C terminus of the chimeric protein. The peptide ligands may include heterologous peptidyl binding motifs, such as short linear motifs (SLiMs). Chimeric proteins with various configurations and methods for their production and use are provided.

Abstract: The instant invention provides methods and compositions related to discovery of c-fos as a therapeutic target for treatment or prevention of neuronal diseases or disorders that are characterized by angiogenesis, or of vascular diseases of the eye and/or retinal degeneration. Therapeutic and/or prophylactic uses and compositions of c-fos inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel c-fos inhibitors are also provided.

Abstract: The application discloses multimeric assemblies packaging one or more active component and their use to carry out nucleic acid regulation or gene editing.

Abstract: The present invention provides ribosomal RNA origami nanostructures and in particular nanostructures comprising RNA staples, composition comprising such origami nanostructures as well as methods for manufacturing such origami structures.

Abstract: The invention relates to double stranded oligonucleotide complexes comprising an antisense oligonucleotide (AON) and a complementary sense oligonucleotide (SON), for use in the deamination of a target adenosine in a sense target RNA sequence in a cell by an ADAR enzyme, wherein at least the nucleotide in the AON that is directly opposite the target adenosine in the target RNA sequence does not have a 2?-O-alkyl modification and the SON comprises nucleotides that are at least complementary to all nucleotides in the AON that do not have a 2?-O-alkyl modification. The invention further relates to methods of RNA editing using the AON/SON complexes of the invention.

Abstract: Disclosed are artificial chemical entities, pharmaceutical compositions comprising such chemical entities and methods using the chemical entities. In some embodiments, the artificial chemical entity comprises a biomarker-bonding portion that selectively binds to a specified biomarker and an immune-response trigger that under in vivo conditions leads to positioning of an antibody Fc region in proximity of the biomarker to which the biomarker-binding portion is bound.

Abstract: Methods for treating, and for identifying novel treatments for, neurodegenerative diseases, as well as animal and cellular models.

Abstract: Provided are methods for inhibiting cancer cell growth comprising contacting the cancer cell with an agent which inhibits the expression of the gene, or the activity of, apolipoprotein B editing catalytic 3G (APOBEC3G). Also provided are methods for identifying agents which can induce or inhibit C>U deamination in RNA driven by apolipoprotein B editing catalytic proteins. The method comprises contacting APOBEC3G with a suitable RNA substrate and determining the extent of C>U deamination under conditions which induce APOBEC driven C>U deamination.

Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.

Abstract: Provided are methods for the diagnosis and treatment of liver cancers such as hepatocellular carcinoma (HCC). In some aspects, the methods comprise administering an inhibitor of STEAP2 to a subject to treat a liver cancer. In some embodiments, a STEAP2 targeting siRNA or antibody is administered to a subject to treat HCC.

Abstract: Provided is a recombinant cell that produces isoprene or terpene, wherein the recombinant cell includes an ability to synthesize isopentenyl diphosphate through a mevalonate pathway (MVA pathway), wherein the recombinant cell lacks an ability to synthesize isopentenyl diphosphate through an endogenous non-mevalonate pathway (MEP pathway), wherein the recombinant cell includes an isoprene synthase gene or a terpene synthase gene as a foreign gene, and wherein the recombinant cell produces, with the expression of the foreign gene, isoprene or terpene having 10, 15, 20, 30, or 40 carbon atoms. The mevalonate pathway is preferably an exogenous mevalonate pathway.

Abstract: The invention relates to methods of modulating the expression of one or more genes in a cell by modulating the multimerization of a transcription factor and/or modulating the formation of enhancer-promoter DNA loops, and thereby modulating the expression of the one or more genes. The invention also relates to treating diseases and conditions involving aberrant gene expression by modulating the multimerization of a transcription factor and/or modulating the formation of enhancer-promoter DNA loops. The invention also relates to methods for screening for compounds that modulate expression of one or more genes in a cell.

Abstract: The present invention relates to yeast with an enhanced ginsenoside-producing ability prepared by changing Ald2, Ald6, Zwf1, and Zms1, a method of preparing the yeast, and a method for producing ginsenosides using the yeast.

Abstract: A soybean cultivar designated 63301112 is disclosed. The invention relates to the seeds of soybean cultivar 63301112, to the plants of soybean cultivar 63301112, to the plant parts of soybean cultivar 63301112, and to methods for producing progeny of soybean cultivar 63301112. The invention also relates to methods for producing a soybean plant containing in its genetic material one or more transgenes and to the transgenic soybean plants and plant parts produced by those methods. The invention also relates to soybean cultivars or breeding cultivars, and plant parts derived from soybean cultivar 63301112. The invention also relates to methods for producing other soybean cultivars, lines, or plant parts derived from soybean cultivar 63301112, and to the soybean plants, varieties, and their parts derived from use of those methods. The invention further relates to hybrid soybean seeds, plants, and plant parts produced by crossing cultivar 63301112 with another soybean cultivar.

Abstract: A soybean cultivar designated 77130123 is disclosed. The invention relates to the seeds of soybean cultivar 77130123, to the plants of soybean cultivar 77130123, to the plant parts of soybean cultivar 77130123, and to methods for producing progeny of soybean cultivar 77130123. The invention also relates to methods for producing a soybean plant containing in its genetic material one or more transgenes and to the transgenic soybean plants and plant parts produced by those methods. The invention also relates to soybean cultivars or breeding cultivars, and plant parts derived from soybean cultivar 77130123. The invention also relates to methods for producing other soybean cultivars, lines, or plant parts derived from soybean cultivar 77130123, and to the soybean plants, varieties, and their parts derived from use of those methods. The invention further relates to hybrid soybean seeds, plants, and plant parts produced by crossing cultivar 77130123 with another soybean cultivar.

Abstract: The present invention generally relates to plants comprising a CRISPR system or parts of a CRISPR system, compositions, containers, polynucleotide, vectors, delivery systems, parts of plants, methods for production, CRISPR systems, and components thereof. Further aspects of the invention include a method for identifying a CRISPR system which is functional in a plant cell and a method for improving a CRISPR system in a plant.

Abstract: Materials and methods for conferring geminivirus resistance to plants or plant cells, and particularly to materials and methods for using CRISPR/Cas or CRISPR/Cpf1 systems to confer resistance to geminiviruses. Materials and methods are described to insert sequence at a double stranded break in a geminivirus genome.

Abstract: The present disclosure relates to the use of recombinant proteins for inducing epigenetic modifications at specific loci, as well as to methods of using these recombinant proteins for modulating the expression of genes in plants.

Abstract: The invention relates to novel plants, seeds and compositions, as well as improvements to plant breeding and methods for creating modifications in plant genomes.

Abstract: A method is disclosed for reducing the level of gossypol in cottonseed. The method generally includes selectively inducing RNA gene silencing in the seed of a transgenic cotton plant, to interfere with expression of the 6-cadinene synthase gene or the ?-cadinene-8-hydroxylase gene in the seed of the cotton plant without substantially affecting expression of that gene in the foliage, floral parts, and roots of the plant. The transgenic cotton plant comprises at least one of a ?-cadinene synthase gene trigger sequence and/or a ?-cadinene-8-hydroxylase gene trigger sequence operably linked to one or more a seed-specific promoter gene sequences, and the trigger sequence(s) is/are able to induce RNA gene silencing when expressed in cottonseed of the plant.

Abstract: The present invention provides a method for increasing the sucrose ester content of a tobacco plant or tobacco cell culture, the method comprising modifying said tobacco plant or tobacco cell culture by inhibiting the activity or expression of a diterpene synthesis gene. The present invention also provides for the use of a diterpene synthesis gene for increasing the sucrose ester content of a tobacco plant or tobacco cell culture, as well as tobacco cells, tobacco plants, tobacco plant propagation materials, harvested leaves, processed tobaccos, or tobacco products obtainable in accordance with the invention.

Abstract: The invention relates to high-protein-content soybeans and methods of producing high-protein-content soybeans. The methods can relate to proteome rebalancing and regulating the abscisic acid (ABA) pathway. The methods can relate to modulating transcription factors such as AiP2. AiP2 modification can increase soybean protein content and indicates the strategic path to alter seed protein is contained within the mechanisms of abscisic acid control of seed development.

Abstract: The present invention relates to a method for producing a useful protein by a plant, including culturing a plant body capable of producing a useful protein in a container while keeping at least a part of the plant body immersed in a liquid medium to allow the plant body to grow. According to the present invention, a useful protein can be stably and efficiently produced by using a plant.

Abstract: This invention relates to the expression a DA1 protein with a mutation that disrupts or inactivates the LIM domain or the LIM-like domain within cells of a plant. This may increase the yield or enhance a yield-related trait of the plant. Methods, plants and plant cells are provide.

Abstract: Provided are isolated polypeptides which are at least 80% homologous to SEQ ID NOs: 2005, 1992-3040, isolated polynucleotides which are at least 80% identical to SEQ ID NOs: 138, 63, 50-1969, nucleic acid constructs comprising same, transgenic cells expressing same, transgenic plants expressing same and method of using same for increasing yield, abiotic stress tolerance, growth rate, biomass, vigor, oil content, photosynthetic capacity, seed yield, fiber yield, fiber quality, fiber length, and/or nitrogen use efficiency of a plant.

Abstract: The present invention includes systems, methods and compositions for increasing trichome formation and/or density in cannabinoid producing plants, such as Cannabis and hemp. Additional aspects of the invention further include systems, methods and compositions for increasing cannabinoid and terpene biosynthetic and storage capacity in Cannabis.

Abstract: Provided herein are genetically modified citrus plants having enhanced resistance to Huanglongbing (HLB) and methods of producing such plants by overexpressing a papain-like cysteine protease (PLCP) polypeptide to overcome the function of Sec-delivered effector 1 (SDE1).

Abstract: The invention generally relates to compositions (including constructs, vectors, and cells) and methods of using such compositions for controlling gene expression. More specifically, the invention relates to use of R-motif sequences and/or uORF sequences to control gene expression.

Abstract: Compositions and methods for conferring resistance to a plant pathogen are provided. Compositions comprising a coding sequence for a polypeptide having antifungal activity are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in any of SEQ ID NO:1-67, or the nucleotide sequence set forth in any of SEQ ID NO:69-81, 83-95, or 97-106, as well as variants and fragments thereof.

Abstract: The present disclosure relates to the genetically modified non-human animals that express a human or chimeric OX40, and methods of use thereof.

Abstract: The disclosure provide cell lines and methods for the production of vectors and viral particles useful in gene therapy.